Latest News
TILT BIO news featured in MedNous January 2025
Poster 163P presented at ESMO Immuno-Oncology 2024
TILT Provides Update on International Clinical Trial Progress with IV Delivery Regimen for Cancer Immunotherapies
Poster 1025P presented at ESMO 2024
TILT Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
TILT featured in an article by Tesi
TILT featured in ONCOLife June 2024 issue
Poster #433 presented at ASCO 2024. TILT-123 and pembrolizumab in ovarian cancer – Phase I data
Poster #137 presented at ASCO 2024. Intravenous delivery of TILT-123 – Phase I data
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense
TILT Biotherapeutics Regains Rights to TILT-123 in the Greater China Area Upon Termination of License Agreement with Biotheus
TILT Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO IO 2023
Late Breaking Abstract and posters from TILT trials presented at SITC 2023
TILT presented four posters at SITC Annual Meeting
TILT Biotherapeutics covered in the Nordic Life Science magazine
First Patient Dosed in Phase I trial studying TILT-123 and anti-PD-L1
TILT Biotherapeutics Announces Close of Financing Round to Advance to Phase II Oncology Immunotherapy Trials
TILT presents a poster on TILT-T115 and TILT-T215 trials at SITC Annual Meeting
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
TILT presents a poster covering updates on TILT-T115 and TILT-T215 trials at CICON — International Cancer Immunotherapy Conference
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC
TILT holds an oral presentation and a poster presentation covering updated on TILT-T115 trial at the SSI Annual Meeting 2022
TILT Biotherapeutics Announces over $10 Million Financing Round and Chair of the Board Appointment
TILT presents TILT-T215 interim data at ASCO 2022
New immunotherapy tools to fight cancer – An article in CORDIS on an EU founded project coordinated by TILT Biotherapeutics (available in 6 languages)
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
TILT Biotherapeutics covered in Nature’s BioPharma Dealmakers
Suomalaisyrityksen syöpälääke kliinisessä kehityksessä
Suomessa ja maailmalla
TILT Biotherapeutics Announces Data at ESMO on its Oncolytic Immunotherapy Platform
TILT publishes a video on intratumoral injection in practice
TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial
TILT Biotherapeutics and MSD to collaborate on clinical trial of adenoviral cancer immunotherapeutic TILT-123 in combination with KEYTRUDA® (pembrolizumab) for ovarian cancer
TILT Biotherapeutics advances cancer immunotherapy clinical trial achieving primary end point in the first cohort
TILT Biotherapeutics announces two patients pass primary safety endpoint in European cancer immunotherapy trial
Press Release: TILT Biotherapeutics secures over EUR 6 million to advance cancer immunotherapies into clinic
Tuija Keinonen joins TILT as Regulatory consultant
TILT Biotherapeutics was featured Tulevaisuuden työelämä 2020. Read the article in Finnish here.
TILT´s CEO Akseli Hemminki interviewed at JP Morgan Biotech Showcase
TILT varautuminen koronatilanteen aiheuttamiin muutoksiin
TILT preparations during the corona pandemic
Jyrki Liljeroos joins TILT as Board Advisor
Springvest organised investment round
João Santos appointed as a Head of Cell Therapy
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc
Watch the interview with TILT Biotherapeutics CEO, Akseli Hemminki, at Biotech Showcase 2020
TILT´s CBO Aino Kalervo attended LSX Investival Showcase in London in November. Watch Aino´s presentation here.
ESMO IO Merit award
TILT Biotherapeutics was featured in the September issue of Business Now. You can read the article in Finnish here.
TILT-Merck
TILT Biotherapeutics was listed as one of the 15 most promising biotech startups in Europe in 2019 by BiotechCity.
Kari Varkila started as a Chief Medical Officer in August 2019
Patent
Nasdaq pitch
STACCATO open PhD position
AACR poster
Víctor Cervera-Carrascón started as a Head of Immunology in December 2018
Riikka Havunen PhD
STACCATO
Victor ECIS award
Claudia Kistler started as a Head of Clinical Operations at TILT in May
View and listen Akseli Hemminki’s pitch at 2018 Bio International Convention held in Boston in June.
Unleashad
Q&A
ECI
IOVC posters
CIMT
EVC Final 2017 – Tech Tour
ESMO IO
SAB
AACR
CITIM
Human vaccinations
Piper
HealthTech
NVGCT
TILT Biotherapeutics DealMakers
TILT Biotherapeutics mentioned
Merck award
Head of Production
Elina Haavisto starts as Head of Regulatory and Riikka Kalliokoski as Lab Manager at TILT.
ATMP classification
ESMO Immuno-Oncology
SITC poster
Poster featuring TILT technology
VIRION meeting 2016
TILT team in September 2016
Head of Preclinical Science Mikko Siurala was awarded oral presentation at the International Conference of Oncolytic Virus Therapeutics, Vancouver, Canada
TILT Biotherapeutics featured in European Biotechnology
Víctor Cervera-Carrascón, an EU funded student working at TILT wins poster award for his work with anti-PD1 checkpoint inhibition enhanced by TILT technology at Finnish Cancer Institute Symposium – Cancer and Immune System.
TILT Posters presented at the American Society of Gene & Cell Therapy 19th Annual Meeting in Washington DC, USA
6.5.2016 TILT / University of Pennsylvania (Carl June group) collaboration featured in an oral presentation at the American Society of Cell and Gene Therapy meeting in Washington, DC
Jan 2016. João Manuel Santos started as a Marie Skłodowska-Curie PhD Student at TILT Biotherapeutics Ltd
Feb 2016. Víctor Cervera Carrascón started as a Marie Skłodowska-Curie PhD Student at TILT Biotherapeutics Ltd
March 2016. Aino Kalervo starts as Head of Business Management at TILT
Feb 2016. Mona Österlund starts as Head of Clinical Operations at TILT
Jan 2016. Elina Koli starts as Head of Quality at TILT
Slush
19.9.2015 TILT technology presented in an invited talk at the European Society of Gene and Cell Therapy meeting
Five open PhD Student positions / ESR ‘Viruses, Immune stimulation and RNA Interference in Oncology – Network (VIRION)
TILT Biotherapeutics featured in Nature Reviews Drug Discovery
TILT Posters presented at the 13th Cancer Immunotherapy Annual Meeting in Mainz, Germany
Suvi Parviainen joins TILT as Head of R&D
First Scientific Advisory Board meeting held
TILT receives 2 year government loan from TEKES
TILT science presented in an invited talk at the European Society of Cell and Gene Therapy
TILT technology featured in an invited presentation at the Oncolytic Viruses Meeting in Oxford, UK
TILT featured in Talouselämä
Akseli Hemminki presents on Oncolytic vaccines for treatment of cancer at the Progress in Vaccination against Cancer meeting in Amsterdam, the Netherlands.
Seed funding round closed following investments by angels, Lifeline Ventures Fund, Finnish government (TEKES) and Finnish Invention Fund (Keksintösäätiö).
TILT Biotherapeutics Ltd is founded
Upcoming Events
Please contact our business development team to meet us at the following events: